Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Benitec Biopharma Reports 100% Response Rate in Interim BB-301 Phase 1b/2a Trial Results

By Public Technologies
  • Benitec Biopharma announced positive interim Phase 1b/2a results for BB-301 in patients with swallowing difficulties caused by oculopharyngeal muscular dystrophy.
  • All nine treated patients responded to therapy, with low-dose improvements sustained through 12 months.
  • High-dose treatment showed greater improvements in throat emptying and functional swallowing capacity than the low dose at three months.
  • No serious adverse events were reported; a pivotal study is planned for mid-2027.
  • Results are available in a poster accepted as a late-breaking abstract at the European Society of Gene and Cell Therapy annual congress.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610280800PRIMZONEFULLFEED9854823) on October 28, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.